Skip to content Skip to sidebar Skip to footer

Newsletter

Tech Stocks

Test text

Rejecting a takeover offer: Here are 6 ASX stocks that did and how it ended for them

Rejecting a takeover offer is a bold step for an ASX company to take. It is turning down sweet quick cash for its shareholders and management. The argument most commonly made to reject them is that any offers are opportunistic and do not appropriately value the company - indeed, those very words are commonly used. The board…

ByNick SundichOctober 14, 2025

1414 Degrees (ASX: 14D) Secures Silicon Battery Technology from George Washington University

1414 Degrees Taps U.S. Innovation to Advance Next-Generation Battery Technology It is not every day that a small Australian energy company steps into the global battery race. Yet today, 1414 Degrees (ASX: 14D) announced an exclusive licence agreement with George Washington University to commercialise a breakthrough silicon nanoparticle technology designed for lithium-ion battery anodes. The opportunity…

ByCharlie YouldenOctober 9, 2025

Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism

Cyclopharm (ASX:CYC) is a rare species - an ASX stock that is approved in the US market. However, its share price has gone in the opposite direction. Cyclopharm has not had as fast an uplift as other companies have had and still makes most of its sales from other jurisdictions. A lawsuit from 4D Medical…

ByNick SundichOctober 8, 2025

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Hear the term 'Activist investors' and you might think of GetUp, the progressive activist group that forced Woolworths to hold an EGM in 2014 in an attempt to limit the maximum bets on poker machines to $1. Or perhaps even of ESG-focused fundies like Australian Ethical (ASX:AEF). The reality is a lot more complicated and…

ByNick SundichOctober 8, 2025

Acusensus (ASX: ACE) Surges 18% on Major USD 22 Million U.S. Contract Win

The AI-Driven Road Safety Company Winning Government Contracts Worldwide Acusensus (ASX: ACE) grabbed investors’ attention today after its share price surged 18 percent on news of a major contract win in the United States. The company secured a deal worth an estimated USD 22 million to deliver automated work zone speed control systems across Connecticut, marking…

ByCharlie YouldenOctober 7, 2025

Weebit Nano’s 185% Rally, Onsemi Breakthrough Brings ReRAM Closer to Reality

Weebit Nano’s onsemi Milestone Strengthens Commercial Outlook After 185% Share Price Surge over the past 6 months Weebit Nano (ASX:WBT) has achieved a significant milestone in its journey toward commercialising its next-generation memory technology, Resistive Random Access Memory (ReRAM). The company has successfully completed the “tape-out” phase — the point where chip designs are finalised…

ByCharlie YouldenOctober 7, 2025

Nuix (ASX:NXL) has fallen 50% in 12 months! But shares may have taken a turn for the better in recent weeks

After closing 2024 with a share price that had more than tripled in 12 months, Nuix (ASX:NXL) has halved so far in 2025...but things might have taken a turn for the better recently, and shares are up 50% in the past 7 weeks. This company has been one of the most controversial companies on the ASX…

ByNick SundichOctober 7, 2025

Fermi Surges 55% in Market Debut After USD 682m IPO

Fermi’s Bold Entry: 55% IPO Rally for a Zero-Revenue Energy AI REIT Fermi (Nasdaq: FRMI) made one of the most dramatic market debuts in recent memory, climbing 55% from its USD 21 IPO price on its first day of trading. Yet this is far from a typical growth stock. Fermi is an early-stage company attempting…

ByCharlie YouldenOctober 2, 2025

Race Oncology Jumps 23% as Researchers Uncover Key Mechanism Behind Lead Cancer Drug

Race Oncology Soars 23% on Breakthrough Discovery Targeting MYC Race Oncology (ASX: RAC) opened strongly, rising 23 percent after releasing new insights into how its lead cancer drug, bisantrene (RC220 Bisantrene, RCDS1), actually works inside the body. The company’s researchers found that the drug attaches to and stabilises DNA and RNA structures known as…

ByCharlie YouldenOctober 2, 2025

Metallium (ASX: MTM) Surges 23% on Glencore Partnership: Full Investor Breakdown

Glencore Deal Sends Metallium (ASX: MTM) Shares Soaring 23% Metallium (ASX: MTM) has quickly become one of the most talked-about names on the ASX, with recent momentum driven by news that could reshape its path forward. The latest catalyst was a memorandum of understanding with a subsidiary of Glencore plc, one of the world’s largest…

ByCharlie YouldenOctober 2, 2025

the Kick-ass Multipurpose WordPress Theme

Tech Stocks

Rejecting a takeover offer: Here are 6 ASX stocks that did and how it ended for them

1414 Degrees (ASX: 14D) Secures Silicon Battery Technology from George Washington University

Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Acusensus (ASX: ACE) Surges 18% on Major USD 22 Million U.S. Contract Win

Weebit Nano’s 185% Rally, Onsemi Breakthrough Brings ReRAM Closer to Reality

Nuix (ASX:NXL) has fallen 50% in 12 months! But shares may have taken a turn for the better in recent weeks

Fermi Surges 55% in Market Debut After USD 682m IPO

Race Oncology Jumps 23% as Researchers Uncover Key Mechanism Behind Lead Cancer Drug

Metallium (ASX: MTM) Surges 23% on Glencore Partnership: Full Investor Breakdown

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Tech Stocks

Stocks in Spotlight

Add Your Heading Text Here